Potential negative effects of the free use of chloroquine to manage COVID‐19 in Colombia

Teherán, Aníbal A.; Camero, Gabriel; Hernández, Carolina; Perez‐Garcia, Luis; Guzmán, Renato A.; Paniz‐Mondolfi, Alberto; Ramírez, Juan David

doi:10.1002/jmv.26059

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously evidence suggested that drugs such as chloroquine (or hydroxychloroquine) with or without azithromycin or clarithromycin, would be useful [75,99,143], nevertheless somes studies showed no significant benefit for patients and concerning risk of adverse effects [149,150]. Other drugs such as lopinavir/ritonavir, remdesivir, among others, may be used in mild to severe, under close medical observation given the frequency of adverse effects [43].…”

Section: Clinical Pathologymentioning

confidence: 99%

An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies

Dhama

Patel

Pathak

et al. 2020

Travel Medicine and Infectious Disease

148

164

View full text Add to dashboard Cite

Coronavirus Disease 2019 (COVID-19), emerged in early December 2019 in China and became a pandemic situation worldwide by its rapid spread to more than 200 countries or territories. Bats are considered as the reservoir host, and the search of a probable intermediate host is still going on. The severe form of the infection is associated with death is mainly reported in older and immune-compromised patients with pre-existing disease history. Death in severe cases is attributed to respiratory failure associated with hyperinflammation. Cytokine storm syndrome associated with inflammation in response to SARS-CoV-2 infection is considered as the leading cause of mortality in COVID-19 patients. COVID-19 patients have thus higher levels of many proinflammatory cytokines and chemokines. The blood laboratory profile of the COVID-19 patients exhibits lymphopenia, leukopenia, thrombocytopenia, and RNAaemia, along with increased levels of aspartate aminotransferase. SARS-CoV-2 infection in pregnant women does not lead to fetus mortality, unlike other zoonotic coronaviruses such as SARS-CoV and MERS-CoV, and there is, to date, no evidence of intrauterine transmission to neonates. Rapid diagnostics have been developed, and significant efforts are being made to develop effective vaccines and therapeutics. In the absence of any virus-specific therapy, internationally, health care authorities are recommending the adoption of effective community mitigation measures to counter and contain this pandemic virus. This paper is an overview of this virus and the disease with a particular focus on SARS-CoV-2/COVID-19 clinical pathology, pathogenesis, and immunopathology, along with recent research developments.

show abstract

Section: Clinical Pathologymentioning

confidence: 99%

An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies

Dhama

Patel

Pathak

et al. 2020

Travel Medicine and Infectious Disease

148

164

View full text Add to dashboard Cite

show abstract

Potential negative effects of the free use of chloroquine to manage COVID‐19 in Colombia

Teherán

Camero²,

Hernández

et al. 2020

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

<p>Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation</p>

Belayneh¹

2020

RRTM

View full text Add to dashboard Cite

COVID-19 is continuing as a big challenge for the globe and several types of research are continued to find safe and effective treatment and preventive options. Although there is a lack of conclusive evidence of their benefit, there is worldwide controversy to use anti-malarial drugs, hydroxychloroquine and chloroquine, for the treatment of COVID-19. FDA issued an emergency use authorization to the use of these drugs for the treatment of COVID-19. On the contrary to the FDA, the European Medicines Agency has warned against the widespread use of these drugs to treat COVID-19. Finally, the WHO declared that clinical trials on these drugs are halted after the devastating findings of the study published in the medical journal called The Lancet. Against this fact, there are several rumors about the irresponsible use of these drugs in Africa for the treatment of COVID-19. This work aimed to review the off-label use of these drugs for the treatment of COVID-19 in African countries against WHO recommendation. Data on the use of these drugs for the treatment of COVID-19 in African countries were searched from credible sources including Scopus, PubMed, Hindawi, Google Scholar, and from local and international media. The study showed that many African countries have already approved at the national level to use these drugs to treat COVID-19 by opposing WHO warnings. In addition to this, falsified and substandard chloroquine products started to emerge in some African countries. The health sectors of the African government should critically compare the risks and benefits before using these drugs. The WHO and African drug regulatory organizations should intervene to stop the off-label use practice of these drugs against the licensed purpose and distribution of falsified and substandard products in the continent.

show abstract

Potential negative effects of the free use of chloroquine to manage COVID‐19 in Colombia

Cited by 3 publications

References 16 publications

An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies

An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies

Potential negative effects of the free use of chloroquine to manage COVID‐19 in Colombia

<p>Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation</p>

Contact Info

Product

Resources

About